The Pennant Group Acquires Texas Home Health Provider

The acquisition was effective May 1, 2021 and will operate under the name Custom Care Home Health.

The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, today announced that it has acquired the assets of Cardiovascular Home Care, which provides home health services in Fort Worth, Texas.

The acquisition was effective May 1, 2021 and will operate under the name Custom Care Home Health.

“Having a strong hospice agency and a number of senior living communities in Dallas, we have carefully looked for the right opportunity to add home health services in the DFW area. This acquisition provides a strong platform for our local leaders to better address the needs of the community,” said Danny Walker, Pennant’s Chief Executive Officer. “Throughout our home health and hospice portfolio, there are dozens of opportunities like this to expand our services and be a solution for patients throughout the care continuum,” he added.

“This agency was founded by talented clinicians who believed in providing the highest standard of patient care,” commented Brent Guerisoli, President of Pennant. Noting that the agency admitted approximately 1,500 patients last year, Mr. Guerisoli added, “Their commitment to clinical excellence is demonstrated by their high quality ratings and strong market reputation. We are thrilled to welcome their talented team and look forward to continuing their tradition of outstanding patient care.”

Mr. Guerisoli reaffirmed that Pennant continues to pursue opportunities to acquire home health, hospice, home care and senior living businesses throughout the United States.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.